IP Library Granted Patent US 11,987,607
Granted Patent B2
US 11,987,607 · App. 18/053,981 · Granted May 21, 2024

Antimicrobial peptides with alpha-core helices

Inventors: Nannette Y. Yount (San Juan Capistrano, CA); Michael R. Yeaman (Redondo Beach, CA)
Assignee: The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
C07K14/4723C07K14/43518C07K14/43522C07K14/43568C07K14/43572C07K14/43581C07K14/463C07K14/465G16B15/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,987,607
App. No.
18/053,981
Granted
May 21, 2024
Kind
B2
Abstract

Computational systems and methods are described for identifying new α-helical antimicrobial peptides using a systemic consensus formula. Newly identified α-helical antimicrobial peptides are tested experimentally and show potent microbiocidal activities.

Claims (8)

1. A method for treating an infection in a patient in need thereof, comprising administering to the patient a polypeptide comprising the amino acid sequence of SEQ ID NO: 3, wherein the peptide is not longer than 60 amino acid residues in length.

2. The method of claim 1 , wherein the peptide is not longer than 50 amino acid residues in length.

3. The method of claim 1 , further comprising administering to the patient an antimicrobial agent.

4. The method of claim 3 , wherein the antimicrobial agent is selected from the group consisting of imipenem, ceftazidime, colistin, chloroquine, artemisinin, vancomycin and daptomycin.

5. The method of claim 1 , wherein the infection is caused by a Gram-negative bacterium.

6. The method of claim 1 , wherein the infection is caused by a Gram-positive bacterium.

7. The method of claim 1 , wherein the infection is caused by a fungus.

8. The method of claim 1 , wherein the administration is subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, or intracranial injection, or infusion.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY NAME PREVIOUSLY RECORDED AT REEL: 67049 FRAME: 765. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded May 6, 2024
From: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
To: THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
Reel/Frame 067329/0210 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 67048 FRAME: 369. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 6, 2024
From: YOUNT, NANNETTE Y.; YEAMAN, MICHAEL R.
To: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
Reel/Frame 067329/0230 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2024
From: YOUNT, NANNETTE Y.; YEAMAN, MICHAEL R.
To: LOS ANGELES BIOMEDICIAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
Reel/Frame 067048/0369 →
CHANGE OF NAME Recorded Apr 9, 2024
From: LOS ANGELES BIOMEDICIAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
To: THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
Reel/Frame 067049/0765 →
Continuity (3)
Division 16612242
Provisional Application 62505013 · May 11, 2017
Related Publication 20230227516A1 · Jul 20, 2023